11/20
04:05 pm
advm
Adverum Biotechnologies Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Adverum Biotechnologies Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
11/20
12:04 am
advm
Adverum Biotechnologies, Inc. (NASDAQ: ADVM) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
High
Report
Adverum Biotechnologies, Inc. (NASDAQ: ADVM) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
11/19
08:20 am
advm
Adverum Biotechnologies, Inc. (NASDAQ: ADVM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
High
Report
Adverum Biotechnologies, Inc. (NASDAQ: ADVM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
11/18
07:12 am
advm
Adverum Biotechnologies Announces Positive 52-Week LUNA and 4-Year OPTIC Results, and Provides Key Pivotal Program Design Elements [Yahoo! Finance]
High
Report
Adverum Biotechnologies Announces Positive 52-Week LUNA and 4-Year OPTIC Results, and Provides Key Pivotal Program Design Elements [Yahoo! Finance]
11/18
07:00 am
advm
Adverum Biotechnologies Announces Positive 52-Week LUNA and 4-Year OPTIC Results, and Provides Key Pivotal Program Design Elements
High
Report
Adverum Biotechnologies Announces Positive 52-Week LUNA and 4-Year OPTIC Results, and Provides Key Pivotal Program Design Elements
11/15
04:05 pm
advm
Adverum Biotechnologies Announces Webcast to Report 52-Week LUNA Phase 2 Clinical Data and 4-Year OPTIC Clinical Data, and to Provide Key Pivotal Program Design Elements
Low
Report
Adverum Biotechnologies Announces Webcast to Report 52-Week LUNA Phase 2 Clinical Data and 4-Year OPTIC Clinical Data, and to Provide Key Pivotal Program Design Elements
11/6
11:09 pm
advm
Adverum Biotechnologies, Inc. (NASDAQ: ADVM) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Medium
Report
Adverum Biotechnologies, Inc. (NASDAQ: ADVM) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
11/5
11:19 am
advm
Adverum Biotechnologies, Inc. (NASDAQ: ADVM) had its price target lowered by analysts at Royal Bank of Canada from $12.00 to $10.00. They now have a "sector perform" rating on the stock.
Low
Report
Adverum Biotechnologies, Inc. (NASDAQ: ADVM) had its price target lowered by analysts at Royal Bank of Canada from $12.00 to $10.00. They now have a "sector perform" rating on the stock.
11/4
07:54 pm
advm
Adverum Biotechnologies (ADVM) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]
Low
Report
Adverum Biotechnologies (ADVM) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]
11/4
05:20 pm
advm
Adverum Biotechnologies: Q3 Earnings Snapshot [Yahoo! Finance]
Low
Report
Adverum Biotechnologies: Q3 Earnings Snapshot [Yahoo! Finance]
11/4
04:46 pm
advm
Adverum Biotechnologies Reports Third Quarter 2024 Financial Results, Provides Corporate Highlights and Updates Anticipated Milestones [Yahoo! Finance]
Low
Report
Adverum Biotechnologies Reports Third Quarter 2024 Financial Results, Provides Corporate Highlights and Updates Anticipated Milestones [Yahoo! Finance]
11/4
04:39 pm
advm
Adverum Biotechnologies Reports Third Quarter 2024 Financial Results, Provides Corporate Highlights and Updates Anticipated Milestones
Low
Report
Adverum Biotechnologies Reports Third Quarter 2024 Financial Results, Provides Corporate Highlights and Updates Anticipated Milestones
10/16
08:00 am
advm
Adverum Biotechnologies Appoints Jason L. Mitchell as Chief Commercial Officer as it Prepares to Initiate Pivotal Program
Medium
Report
Adverum Biotechnologies Appoints Jason L. Mitchell as Chief Commercial Officer as it Prepares to Initiate Pivotal Program
9/5
07:30 am
advm
Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
9/4
04:05 pm
advm
Adverum Biotechnologies to Participate in Upcoming Fall Investor Conferences
Low
Report
Adverum Biotechnologies to Participate in Upcoming Fall Investor Conferences